

#### TB Infection in the Pediatric Population

#### **Testing and Treatment**

David J. Cennimo, MD, FACP, FAAP, FIDSA Associate Professor of Medicine and Pediatrics Associate Dean of Education – VANJHCS Rutgers New Jersey Medical School

Rutgers, The State University of New Jersey

1

#### RUTGERS

#### Disclosures

- No financial conflicts or disclosures
- Heavily utilizes AAP and CDC approved guidance
- New TB infections in children are a sentinel health event

#### Outline

- Epidemiology
- Differences and Similarities
- TB Exposure
  - Risk Assessment
  - Testing
  - Window Prophylaxis
- TB Infection
  - Education
  - Treatment

#### **Definitions**

- TB Exposure
  - Asymptomatic
  - TST/IGRA negative
  - CXR normal
- TB Infection
  - AKA LTBI
  - Asymptomatic
  - TST/IGRA positive
  - CXR normal or calcifications
- TB Disease
  - Symptomatic
  - TST/IGRA positive (can be negative)
  - CXR abnormal (usually)

3











#### LTBI – CDC Estimates

- Up to 13 million people in the US with LTBI
- Reactivation of LTBI

   Risk adjusted by co-morbidities
   Future therapies
- LTBI →TB disease is responsible for approx. 80% of US TB cases
- · Remember sentinel event

- Active TB risk
- · Reactivation or Primary
- Children
  - 40 to 50% infants
  - 5 to 15% children
    - Risk highest in the 1 to 2 years after infection

https://www.cdc.gov/tb/hcp/clinical-overview/latent-tuberculosis-infection.html 7/1/2024

- Adult data
  - 5 to 10% lifetime risk
  - 50% of the risk in the first 2 years



# TESTING

RUTGERS

#### 11

#### RUTGERS

#### **Diagnosis of TB Infection**

- TST
  - Various criteria for "positive"
  - Limitations
    - Observer variability
    - Return for reading
    - Cross reacting antigens
- Interferon Gamma Release Assays (IGRA)
  - Lymphocytes stimulated by M. tuberculosis Ag
  - Does not recognize BCG
  - Limited data on accuracy in young children and immunosuppressed
    - Limited data <2yo</li>
    - Gaining acceptance
    - Interpretation of "indeterminant"

RUTGERS		Table 3.75. Tuberculin Skin Test (TST) and IGRARecommendations for Infants, Children, and Adolescents <sup>a</sup>
Travel Question >2 weeks? Exposure?		<ul> <li>Children for whom immediate TST or IGRA is indicated<sup>b</sup>:</li> <li>Contacts of people with confirmed or suspected contagious tuberculosis (contact investigation)</li> <li>Children with radiographic or clinical findings suggesting tuberculosis disease</li> <li>Children immigrating from countries with endemic infection (eg, Asia, Middle East, Africa, Latin America, countries of the former Soviet Union), including international adoptees</li> <li>Children with history of significant<sup>e</sup> travel to countries with endemic infection who have</li> </ul>
Consider delaying testing 8-10 weeks	<b>_</b> /	substantial contact with the resident population <sup>d</sup> Children who should have annual TST or IGRA: • Children living with HIV infection
		<i>Children at increased risk of progression of TBI to TB disease:</i> Children with other medical conditions, including diabetes mellitus, chronic renal failure, malnutrition, congenital or acquired immunodeficiencies, and children receiving tumor necrosis factor (TNF) antagonists, deserve special consideration. Underlying immune deficiencies associated with these conditions theoretically would enhance the possibility for progression to severe disease. Initial histories of potential exposure to tuberculosis should be included for all these patients. If these histories or local epidemiologic factors suggest a possibility of exposure, immediate and periodic TST or IGRA should be considered. <b>A TST or IGRA should be performed before initiation of immunosuppressive therapy, including prolonged systemic corticosteroid</b>
		administration, organ transplantation, use of TNF-alpha antagonists or blockers, or other immunosuppressive therapy in any child requiring these
AAP Red Book 2021-2024		treatments.

RUTGERS	Pediatric Tuberculosis (TB) Risk Assessment	Runo Gle Ins	GERS abal Tuberculosis titute	
	Please select Yes or No for each of the following questions to assist your child's pediatrician:		NJ Health	
	Does your child have any symptoms of T8 (cough, fever, night sweats, loss of appetite, weight loss, less playful or energetic, showing signs of being more tired than usual)?	O Yes	0 No	
	Has your child spent time with anyone sick with TB?	) Yes	O No	
	In the last 12 months, has your child lived with or spent significant time with anyone with a long-lasting cough?	) Yes	O No	
	Has your child had a chest X-ray in the past year?		O No	
	TB is more common in countries in Asia, the Middle East, Africa, Latin America, Eastern Europe and the fe	ormer Sovie	t Union	
https://globaltb.nims.rutgers.edu/education	Were you or your child born in a country that is in an area listed above?	) Yes	O No	
	In the past 2 years, have you or your child traveled to a country that is in an area listed above?	O Yes	O No	
aimaterials/productfolder/PEDS looi.pnp	If yes, did you or child spend most of the time with family and friends or other people in the community?	O Yes	O No	
	In the past 2 years, have you had visitors from outside of the U.S. visit your home for at least 14 days?	) Yes	O No	
	If yes, please write which country they visited from:			
	Does your child have HIV infection?	⊖ Yes	0 No	
	Does your child have diabetes?	) Yes	O No	
	Does your child have a serious kidney disease?	⊖ Yes	○ No	
	Has your child been diagnosed with a weakened immune system?	O Yes	O No	
	If yes, is your child taking medication for this?	O Yes	O No	
	Is your child taking medication for nephrotic syndrome (a kidney disorder), rheumatoid arthritis, Crohn's disease, or similar conditions?	O Yes	O No	
	Is your child currently taking steroids, or have they ever taken steroids for 2 weeks or more?	⊖ Yes	O No	
	Has your child had an organ transplant?	⊖ Yes	O No	



Rutgers	
TST or IGRA Which is really better? Sensitivity • TST 80% (70-90) • QFN TB 83% (75-92) • T-SPOT 84% (63-100)	Specificity         • TST       85% (63-100)         • QFN TB       91% (78-100)         • T- SPOT       94% (87-100)
<ul> <li>IGRA indeterminate rate 3-6% (Young age, helminth, immunosuppression)</li> </ul>	Mandalakas, et al. IJTLD 2011

# LTBI EVALUATION AND TREATMENT

#### 17

#### RUTGERS

#### **Diagnosis of Latent Infection**

- Positive tuberculin skin test (TST) or Interferon Gamma release assay (IGRA)
- Normal CXR or evidence of healed infections (calcified granuloma in lungs or calcification in lymph nodes)
- No signs or symptoms of TB disease

2 view CXR in <5 y/o Read by pediatric radiologist



Thorough H&P

# Rutgers

## Varied Manifestations of TB Disease



Figure 1: Radiological presentation of tuberculosis in childhood (A) Miliary tuberculosis. (B) Hilar lymphadenopathy. (C) Cavitating lung disease (adult type).

Newton, et al. Lancet ID 2008





#### RUTGERS

## Abnormal but not Suggestive of TB

- 2 years old
- Afebrile
- Wheezing
- Consider repeating



hyperinflation with flattened diaphragms, peribronchial thickening with subsegmental atelectasis

Friedman et al. BMJ 2021

#### **Symptom Screen**

- Cough >3 weeks
- Hemoptysis
- Weight loss
- · Fever, chills, night sweats
- Dyspnea
- Fatigue
- · Chest pain



# Rutgers

Usually not an Emergency

# LTBI TREATMENT

СОМ	MONLY USED (for those infected consult an expe	RUTGERS			
REGIMEN	DOSAGE		COMMENTS	Global Tuberculosis	
12 Weeks of Once-Weekly Isoniazid (INH) Plus Rifapentine	2-11 Years INH: 25 mg/kg; rounded up to the nearest 50 or 100 mg (max 900 mg)	≥12 Years INH: 15 mg/kg rounded up to the nearest 50 or 100 mg (max 900 mg)	Preferred by most experts for treatment of LTBI in children ≥2 years of age Not indicated for: Children <2 years of age Children with <i>M.tb</i> infection that is presumed resistant to INH and/or RIF Children who had prior adverse events or	Institute New Jersey Medical School	
Administration: DOT or SAT <sup>2</sup> Completion Criteria: 12 doses within 16 wks.	<b>Rifapentine:</b> 10-14,0 kg: 300 mg 14,1-250 kg: 450 mg 25,1-32.0 kg: 600 mg 32,1-49,9 kg: 750 mg ≥50.0 kg: 900 mg		hypersensitivity to INH, RIF, or rifapentine > Pregnant adolescents • Pill burden is substantial for young children and sometimes is not well tolerated • Should take with food containing fat, if possible • Rifapentine may not be readily available		
4 Months of Daily Rifampin (RIF) Administration: SAT <sup>2</sup> Completion Criteria: 120 doses within 6 mos.	15-20 mg/kg; max 600 mg		<ul> <li>Widely used in children and adolescents</li> <li>Continuous daily therapy is required</li> <li>Consider drug-drug interactions (see next column)</li> </ul>		
6 or 9 Months of Daily INH <sup>3</sup> Administration: SAT <sup>2</sup> Completion Criteria: <u>6 mo. regimen</u> : 180 doses within 9 mos. <u>9 mo. regimen</u> : 270 doses within 12 mos.	10-15 mg/kg; max 300 mg		<ul> <li>Many providers use the INH regimen only when a rifamycin-based regimen cannot be used; long duration can result in poor adherence and lower completion rates</li> <li>Although 9 mos. duration is recommended for children (including those with HIV or other immunosuppression), CDC and many experts accept 6 consecutive mos. of uninterrupted daily therapy as adequate</li> </ul>	For additional resources	



#### RUTGERS

# <list-item> **12 Dose INH + RPT (3HP) Recommendations** equal alternative to 9 months INH in otherwise healthy individuals ≥ 12 years old + log risk for TB disease. a Cose contat Becent converte Fibrotic changes on CXR HV not on ART, otherwise healthy Others considered on an individual basis if circumstances deem INH-RPT to be a better choice (likelihood of completion should be considered)

#### INH and Rifapentine for 12 weeks (3HP)

- Efficacy was similar
- 82% in INH-RPT vs. 69% completion in standard therapy group
- Fewer adverse events in INH-RPT arm
- More hepatotoxicity in INH alone group
- More 'possible hypersensitivity' reactions in INH-RPT

#### RUTGERS

#### **INH-RPT NOT Recommended**

- Children < 2 years old
- HIV on ART
- Pregnancy, or likely to become pregnant during treatment
- Presumed INH or RIF resistance
- Prior adverse effects with INH or rifamycins

#### Parent/caregiver education

- · Use translator if needed
- · Review reason for treatment
  - Future risks
  - School concerns
- · Shared decisions
  - Duration and frequency
  - Ease of dosing
- · Review regimens
  - 12 weekly big doses vs. 4 months of daily smaller doses
  - Rifampin: contact lenses, empty stomach, before bedtime?
- · Review side effects
  - Rifampin: orange body fluid, drug interactions (OCP), rashes, liver toxicity, flu-like symptoms
  - INH: liver toxicity, peripheral neuropathy, rash

31

#### RUTGERS

#### **Pyridoxine supplementation**

- Rarely needed in children receiving INH
- Exclusively breastfed infants receiving INH

   1mg/kd/day
  - Not indicated if only the mother is taking INH
- · Meat and milk deficient diets
- Nutritional deficiency
- Symptomatic HIV infected children
- · Pregnant adolescents

https://www.cdc.gov/tb/topic/treatment/pregnancy.html; Loveday, et al. Int J Tuberc Lung Dis 2020





#### **Treatment Adherence**

- · Monthly follow-ups
- · Charts, phone reminders
- Young children
  - INH: crushed tablet (not suspension)
  - Rif: open capsule
  - Mix with spoonful of food
- Infants
  - Formula or breast milk via nipple
- DOT, school RN, pediatrician



- Mark off your calendar every time your child takes a pill.
- Keep the medicine in a place where you cannot miss it, but out of the reach
   of children.









## RUTGERS

#### **Treatment of Exposure Younger than 5 years**

- No evidence of active TB disease
- Normal immune system
- Normal physical exam
- Negative TST/IGRA
- Negative CXR
- Break infectious contact
- Monitor for signs of active TB disease

- Initiate Window Prophylaxis
  - ASAP (Day of evaluation)
  - Presumptive LTBI treatment
  - INH or RIF (next slide)
- Repeat TST/IGRA in 8+
   weeks after contact is broken
  - Negative
    - Stop
  - Positive
    - Continue to complete LTBI Tx

AAP Red Book 2024-2027

#### **Choosing Window Prophylaxis**

#### INH

- 10-15 mg/kd/day (Max 300)
- 100 and 300 mg pills
  - Ease of dosing
- Better CNS penetration
  - Preferred <12 months old</li>
  - Consider <2 years old</li>
- Longer duration for LTBI

#### RIF

- 15-20 mg/kg/day (Max 600)
- 150 and 300 mg capsules
   Ease of dosing
- Shorter duration for LTBI
- Preferred >2 years old

41

#### RUTGERS **Evaluation of Window Prophylaxis** Greater Houston area, 841 children <5 exposed from 2007-2017 • 10.6% not started on window prophylaxis Table 1. Characteristics of 752 children exposed to index - 85% already tested negative (missed opportunity) tuberculosis patients, index patients, and index case Mycobacterium tuberculosis isolates, Houston, Texas, USA, - 9% family refused 2007-2017 Characteristic Value\* 752 received prophylaxis ٠ Demographics Age, y, median (interquartile range) - 97.1% INH 2.4 (1.2-3.6) Sex - 2.7% RIF 380 (50.5) F Μ 372 (49.5) - No hepatotoxicity Race/ethnicity 493 (65.6) ٠ 37 (4.9%) converted Hispanic Black 141 (18.8) - Conversion associated with parental index case Asian 78 (10.4) White 30 (4.0) Not associated with smear+ index case Biracial 10 (1.3) Residing in home of index patient Yes 311 (41.4) No 441 (58.6) Index patient microbiology Acid-fast bacilli smear positive 513 (68.2) Cruz, A and Starke, J Emerg. Infect. Dis. 2019 Acid-fast bacilli culture positive 680 (90.4)

#### Use Source Case Data if Available

- Symptoms for how long?
- Cough for how long?
  - Exposure amount? Cohabitation Don't use strict definition
- · Chest imaging: Cavitary vs. non-cavitary? Miliary? Laryngeal?
- Sputum?
  - AFB smear results
  - Some data for highly smear positive cases too weak to cough vigorously
  - Cases not equally contagious over time
- · When treatment started?
- CULTURE DATA

43

#### RUTGERS

#### **MDR Contacts**

- WHO guidelines for LTBI: Use Levofloxacin x 6 months "along with other TB medicines, such as EMB (or Ethionamide) if tolerated"
- Newer TB medications ?
  - No data for Bedaquiline in kids under 5 years
  - No data for Pretomanid in kids < 15 years
  - Data for Delamanid for >5 years and possibly (per WHO guidelines) 3-5 year olds (uncertain, how the capsules are absorbed if they need to be broken/crushed)
- New WHO operation handbook on TB (2022)
  - Preliminary dosing down to 3 kgs for both Bedaquiline and Delamanid
  - No peds data for Pretomanid
- · Phone many friends

# **PRACTICE CASES**

45

#### RUTGERS

## 3-year-old without symptoms

- PPD placed at insistence of preschool
- 6mm induration at 48 hours
- Next steps?





#### Let's Say the IGRA Is Positive

- Evaluate for symptoms of TB
  - No fever
  - No respiratory symptoms
  - Normal activity, appetite, energy level
- Physical exam
  - No nodes
  - Clear lungs
  - Normal in all aspects
- CXR
  - Normal

- Initiate LTBI Tx
- Rifampin 15-20 mg/kg/day x 120 doses
   OR
- Isoniazid 10-15 mg/kg/day x 180 or 270 doses

#### 49

#### RUTGERS

#### 3-year-old without significant history

- Parent admitted with 4 weeks of progressive cough and chest pain
- 3+ AFB smear positive
- RUL cavity
- What do you want to know?

#### **Index Case**

- Smear 3+ and cavities
- · 4 weeks of symptoms and close contact
- High risk of transmission
- PCR?
  - Confirm M. tuberculosis
  - Rifampin resistance?
- Culture data
  - Probably too soon
- · Risks of resistance

51

# Rutgers

- Evaluate for symptoms of TB
  - No fever
  - No respiratory symptoms
  - Normal activity, appetite, energy level
- Physical exam
  - No nodes
  - Clear lungs
  - Normal in all aspects
- CXR
  - Normal
- IGRA or PPD negative

- Initiate Window Prophylaxis

   Rifampin 15-20 mg/kg/day OR Isoniazid 10-15 mg/kg/day
- Repeat original TB screening 8-10 week after contact broken
- If negative, stop treatment
- If positive, continue
  - Rifampin 15-20 mg/kg/day x 120 doses
    - OR
  - Isoniazid 10-15 mg/kg/day x 180 or 270 doses

